Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07093580 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants

StatusRecruiting
PhasePhase 1
SponsorShionogi
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 1 month later May 26, 2027 → Jun 30, 2028
See other at-risk trials from Shionogi

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from May 26, 2027 to Jun 30, 2028
    • Eligibility criteria expanded, about 9 words
  2. 2 versions Re-verified since Aug 12, 2025, no change to tracked fieldsv3-v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 21, 2025 to Jul 29, 2025
    • Site details revised at 2 of 2 sites
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Shionogi
45 trials monitored
See 2 trials at risk
The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics (PK) of single- and multiple-dose administration of S-892216-LAI in healthy adults.
Trial Details
NCT Number NCT07093580
Lead Sponsor Shionogi
Conditions
(from sponsor)		 Healthy Participants
Related terms COVID-19
Enrollment 98 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov